![](/img/cover-not-exists.png)
The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Emile R. Mohler III, Christie M. Ballantyne, Michael H. Davidson, Markolf Hanefeld, Luis M. Ruilope, Joel L. Johnson, Andrew ZalewskiVolume:
51
Year:
2008
Language:
english
DOI:
10.1016/j.jacc.2007.11.079
File:
PDF, 265 KB
english, 2008